Therapy Focus- The Next Multiple Sclerosis Battleground
Oct. 1, 2015 1:19 PM ET | Roche’s (OTCQX:RHHBY) boast on Monday to have in ocrelizumab the first project to…
Natalizumab ( Tysabri ) Reported To Be a Safe and Effective Therapy for Pediatric Multiple Sclerosis
October 1, 2015 A new study recently published in the journal BMC Neurology revealed that natalizumab (TYSABRI) is a safe…
Stuart Schlossman
FDA Accepts New Drug Application for Osmotica Pharmaceutical’s Ontinua ER for Spasticity in Multiple Sclerosis
October 1, 2015 Osmotica Pharmaceutical Corp. recently announced that the FDA accepted its New Drug Application (NDA) for OntinuaTM ER. The application…
Stuart Schlossman
Brain-specific B Cells’ Reactivity Determines Glatiramer Acetate Therapy Success in MS Patients
Sept 24, 2015 In a new study entitled “The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in…
Stuart Schlossman
Possible JC Virus Vaccination Offers Important Implications for MS Treatment
Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for JC virus with important…
Stuart Schlossman
BREAKING MS NEWS: Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study
Phase III study meets primary endpoint in debilitating form of multiple sclerosis with no approved treatments Ocrelizumab is the first…
Stuart Schlossman
Ocrelizumab: a Promising New Treatment for Multiple Sclerosis with Minimal Side Effects
On September 16, 2015, Swiss pharmaceutical company Roche announced that ocrelizumab, a drug originally designed to treat rheumatoid arthritis that saw its…
Stuart Schlossman
Special Report: Oral Treatments for MS
In the past few years, research has lead to the approval of new oral treatment options for the treatment of…
Stuart Schlossman
Merck Prepares to File for European Marketing Authorization for Cladribine Tablets as a Multiple Sclerosis Therapy
September 14, 2015 Merck recently reported its intention to file for European registration of its product candidate for relapsing multiple sclerosis –…
Stuart Schlossman
Biogen Obtains Exclusive Rights Over Promising MT-1303 Drug for Autoimmune Diseases, Multiple Sclerosis
Sept 10, 2015 Biogen recently announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), a research-driven pharmaceutical company based in Japan, to…
Stuart Schlossman
